Download PDF
Semin Thromb Hemost 2019; 45(05): 514-522
DOI: 10.1055/s-0039-1688444
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hemostatic Abnormalities in Dementia: A Systematic Review and Meta-Analysis

Cristina de Mello Gomide Loures
1   Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Rita Carolina Figueiredo Duarte
1   Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Marcos Vinícius Ferreira Silva
1   Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Walter Batista Cicarini
1   Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Leonardo Cruz de Souza
2   Department of Medical Clinic, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Paulo Caramelli
2   Department of Medical Clinic, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Karina Braga Gomes Borges
1   Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
,
Maria das Graças Carvalho
1   Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
› Author Affiliations Funding CNPq, CAPES, and FAPEMIG agencies provided financial support. LCS, PC, KBG and MGC are grateful to CNPq Research Fellowship.
Further Information

Publication History

Publication Date:
16 May 2019 (online)

    Permissions and Reprints

Abstract

Alzheimer's disease (AD) is considered the most frequent cause of dementia. It is known that vascular risk factors play an important role in the development and progression of this condition. Alterations in vascular walls represent documented findings in patients with AD and other dementias affecting elderly people. The authors performed a systematic review and meta-analysis, aiming to synthesize observational studies that evaluated how the hemostatic system may contribute to cognitive decline in the elderly, using papers published until April 2018 and as indexed in Medline (PubMed), Scopus, Web of Science, ScienceDirect, Lilacs, Cinahl, PsycINFO, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. Among 5,278 studies identified, 32 were included in the final synthesis, and these included 485 patients with mild cognitive impairment, 568 with vascular dementia (VD), 1,781 with AD, and 2,855 participants without dementia. AD patients had increased plasma von Willebrand factor (VWF) (standardized mean difference [SMD]: 2.53; 95% confidence interval [CI]: 0.10–4.95), D-dimer (SMD: 0.50; 95% CI: 0.35–0.66), plasminogen activator inhibitor-1 (SMD: 3.34; 95% CI: 1.01–5.67), thrombomodulin (SMD: 1.08; 95% CI: 0.53–1.62), and homocysteine levels (SMD: 0.65; 95% CI: 0.15–1.15). In contrast, the VD group showed increased fibrinogen levels (SMD: 0.77; 95% CI: 0.13–1.41), activated factor VII (SMD: 0.36; 95% CI: 0.05–0.67), factor VIII (SMD: 0.57; 95% CI: 0.22–0.91), VWF (SMD: 2.34; 95% CI: 0.38–4.29), D-dimer (SMD: 1.14; 95% CI: 0.51–1.78), and homocysteine (SMD: 2.17; 95% CI: 1.67–2.68). AD showed an elevation in some markers of endothelial dysfunction, whereas VD presented mostly an involvement of coagulation cascade components.

Keywords

alzheimer's disease - cognitive decline - dementia - hemostasis

Author Contribution

C. M. G. Loures collected the data, analyzed the data, and drafted the manuscript. R. C. F. Duarte and M. V. F. Silva collected the data. W. B. Cicarini assisted in the statistical analysis. L. C. Souza, P. Caramelli, and K. B. G. Borges contributed to the revision of the manuscript. M. G. Carvalho contributed to the handwriting and revision of the manuscript. The manuscript has been read and approved for submission to Journal of Thrombosis and Haemostasis by all authors.


Supplementary Material

 

  • References

  • 1 Burlá C, Camarano AA, Kanso S, Fernandes D, Nunes R. [A perspective overview of dementia in Brazil: a demographic approach [in Portuguese]. Cien Saude Colet 2013; 18 (10) 2949-2956
    CrossrefPubMedGoogle Scholar
  • 2 Abreu IDA, Forlenza OV, Barros HL. Alzheimer disease: correlation between memory and autonomy. Arch Clin Psychiatry 2005; 32: 131-136
    CrossrefPubMedGoogle Scholar
  • 3 Esquerda-Canals G, Montoliu-Gaya L, Güell-Bosch J, Villegas S. Mouse models of Alzheimer's disease. J Alzheimers Dis 2017; 57 (04) 1171-1183
    CrossrefPubMedGoogle Scholar
  • 4 Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016; 12 (04) 459-509
    CrossrefPubMedGoogle Scholar
  • 5 Kang S, Lee YH, Lee JE. Metabolism-centric overview of the pathogenesis of Alzheimer's disease. Yonsei Med J 2017; 58 (03) 479-488
    CrossrefPubMedGoogle Scholar
  • 6 Mucke L. Neuroscience: Alzheimer's disease. Nature 2009; 461 (7266): 895-897
    PubMedGoogle Scholar
  • 7 Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012; 2012: 756357
    PubMedGoogle Scholar
  • 8 Shadfar S, Hwang CJ, Lim MS, Choi DY, Hong JT. Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents. Arch Pharm Res 2015; 38 (12) 2106-2119
    CrossrefPubMedGoogle Scholar
  • 9 Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011; 25 (01) 5-13
    CrossrefPubMedGoogle Scholar
  • 10 Di Marco LY, Farkas E, Martin C, Venneri A, Frangi AF. Is vasomotion in cerebral arteries impaired in Alzheimer's disease?. J Alzheimers Dis 2015; 46 (01) 35-53
    CrossrefPubMedGoogle Scholar
  • 11 Reijmer YD, van Veluw SJ, Greenberg SM. Ischemic brain injury in cerebral amyloid angiopathy. J Cereb Blood Flow Metab 2016; 36 (01) 40-54
    PubMedGoogle Scholar
  • 12 Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer's disease. Neurobiol Dis 2017; 107: 41-56
    CrossrefPubMedGoogle Scholar
  • 13 Franchini M, Veneri D, Lippi G. Inflammation and hemostasis: a bidirectional interaction. Clin Lab 2007; 53 (1-2): 63-67
    PubMedGoogle Scholar
  • 14 Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state. Thromb Res 2013; 131 (03) 191-197
    CrossrefPubMedGoogle Scholar
  • 15 Liberati A, Altman DG, Tetzlaff J. , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62 (10) e1-e34
    CrossrefPubMedGoogle Scholar
  • 16 Quinn TJ, Gallacher J, Deary IJ, Lowe GD, Fenton C, Stott DJ. Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes. J Thromb Haemost 2011; 9 (08) 1475-1482
    CrossrefPubMedGoogle Scholar
  • 17 Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: Green S, ed. The Cochrane Collaboration, 2011. http://handbook.cochrane.org
  • 18 Endnote x7. Clarivate Analytics, Thomson Reuters; 2013
    PubMed
  • 19 Wells GA, Shea B, Higgins JP, Sterne J, Tugwell P, Reeves BC. Checklists of methodological issues for review authors to consider when including non-randomized studies in systematic reviews. Res Synth Methods 2013; 4 (01) 63-77
    CrossrefPubMedGoogle Scholar
  • 20 Review Manager (RevMan). Version 5.3. ed: The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre; 2014
  • 21 Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study. Exp Gerontol 2014; 50: 114-121
    CrossrefPubMedGoogle Scholar
  • 22 Wang RT, Jin D, Li Y, Liang QC. Decreased mean platelet volume and platelet distribution width are associated with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2013; 47 (05) 644-649
    CrossrefPubMedGoogle Scholar
  • 23 Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of platelet activation with vascular cognitive impairment: implications in dementia development?. Curr Vasc Pharmacol 2014; 12 (01) 152-154
    CrossrefPubMedGoogle Scholar
  • 24 Kim SM, Song J, Kim S. , et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol 2011; 11: 51
    CrossrefPubMedGoogle Scholar
  • 25 Oh J, Lee HJ, Song JH, Park SI, Kim H. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease. Exp Gerontol 2014; 60: 87-91
    CrossrefPubMedGoogle Scholar
  • 26 Kim G, Kim H, Kim KN. , et al. Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. J Alzheimers Dis 2013; 33 (03) 853-862
    CrossrefPubMedGoogle Scholar
  • 27 Piazza F, Galimberti G, Conti E. , et al. Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease. Neurobiol Aging 2012; 33 (02) 226-233
    CrossrefPubMedGoogle Scholar
  • 28 Andreoli VM, Ferrari S, Sirtori CR, Biasi G, Morandini M. Plasma lipids and coagulation in patients with arteriosclerotic dementia. J Neurol Neurosurg Psychiatry 1974; 37: 981-986
    CrossrefPubMedGoogle Scholar
  • 29 Alonso DF, Farias EF, Famulari AL, Dominguez RO, Kohan S, de Lustig ES. Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia. J Neurol Sci 1996; 139 (01) 83-88
    PubMedGoogle Scholar
  • 30 Gallacher J, Bayer A, Lowe G. , et al. Is sticky blood bad for the brain?: hemostatic and inflammatory systems and dementia in the Caerphilly Prospective Study. Arterioscler Thromb Vasc Biol 2010; 30 (03) 599-604
    CrossrefPubMedGoogle Scholar
  • 31 Stott DJ, Spilg E, Campbell AM, Rumley A, Mansoor MA, Lowe GDO. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001; 12 (08) 651-657
    CrossrefPubMedGoogle Scholar
  • 32 Ban Y, Watanabe T, Suguro T. , et al. Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 2009; 16 (03) 179-187
    CrossrefPubMedGoogle Scholar
  • 33 Hagnelius NO, Boman K, Nilsson TK. Fibrinolysis and von Willebrand factor in Alzheimer's disease and vascular dementia--a case-referent study. Thromb Res 2010; 126 (01) 35-38
    CrossrefPubMedGoogle Scholar
  • 34 Mari D, Parnetti L, Coppola R. , et al. Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. Thromb Haemost 1996; 75 (02) 216-218
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Liang QC, Jin D, Li Y, Wang RT. Mean platelet volume and platelet distribution width in vascular dementia and Alzheimer's disease. Platelets 2014; 25 (06) 433-438
    CrossrefPubMedGoogle Scholar
  • 36 Carcaillon L, Gaussem P, Ducimetière P. , et al. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. J Thromb Haemost 2009; 7 (12) 1972-1978
    CrossrefPubMedGoogle Scholar
  • 37 Mancinella A, Mancinella M, Carpinteri G. , et al. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Arch Gerontol Geriatr 2009; 49 (Suppl. 01) 185-194
    CrossrefPubMedGoogle Scholar
  • 38 Matsuoka S, Fukuuchi Y, Tomita M, Tanahashi N, Takeda H. Differences in erythrocyte aggregability between multi-infarct dementia and Alzheimer's disease. J Stroke Cerebrovasc Dis 1993; 3 (02) 102-105
    CrossrefPubMedGoogle Scholar
  • 39 Zhang L, Liu N, Zhang J, Zhang H, Zhang Y. Clinical research of homocysteine, high-sensitive C-reactive protein and D-Dimer in patients with vascular dementia. Pak J Pharm Sci 2017; 30 (4(Suppl.)): 1445-1447
    PubMedGoogle Scholar
  • 40 Domínguez RO, Marschoff ER, Guareschi EM, Famulari AL, Pagano MA, Serra JA. ; Collaborative Group for the Study of the Oxidative Stress and Related Abnormalities. Homocysteine, vitamin B 12 and folate in Alzheimer's and vascular dementias: the paradoxical effect of the superimposed type II diabetes mellitus condition. Clin Chim Acta 2005; 359 (1-2): 163-170
    CrossrefPubMedGoogle Scholar
  • 41 Giambattistelli F, Bucossi S, Salustri C. , et al. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging 2012; 33 (08) 1633-1641
    CrossrefPubMedGoogle Scholar
  • 42 Thambisetty M, Simmons A, Hye A. , et al; AddNeuroMed Consortium. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 2011; 6 (12) e28527
    CrossrefPubMedGoogle Scholar
  • 43 Zamolodchikov D, Chen ZL, Conti BA, Renné T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A 2015; 112 (13) 4068-4073
    CrossrefPubMedGoogle Scholar
  • 44 Zamolodchikov D, Strickland S. The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII: reply. J Thromb Haemost 2016; 14 (07) 1489
    CrossrefPubMedGoogle Scholar
  • 45 Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. Arch Neurol 1998; 55 (04) 530-536
    CrossrefPubMedGoogle Scholar
  • 46 Borroni B, Volpi R, Martini G. , et al. Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. Alzheimer Dis Assoc Disord 2002; 16 (03) 150-155
    CrossrefPubMedGoogle Scholar
  • 47 Yesil Y, Kuyumcu ME, Cankurtaran M. , et al. Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer's disease (AD). Arch Gerontol Geriatr 2012; 55 (02) 257-260
    CrossrefPubMedGoogle Scholar
  • 48 Koç ER, Uzar E, Çirak Y, Parlak Demir Y, Ilhan A. The increase of mean platelet volume in patients with Alzheimer disease. Turk J Med Sci 2014; 44 (06) 1060-1066
    CrossrefPubMedGoogle Scholar
  • 49 Piletz JE, Sarasua M, Whitehouse P, Chotani M. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol Aging 1991; 12 (05) 401-406
    CrossrefPubMedGoogle Scholar
  • 50 Davies TA, Long HJ, Tibbles HE. , et al. Moderate and advanced Alzheimer's patients exhibit platelet activation differences. Neurobiol Aging 1997; 18 (02) 155-162
    CrossrefPubMedGoogle Scholar
  • 51 Kozubski W, Swiderek M, Kloszewska I, Gwozdzinski K, Watala C. Blood platelet membrane fluidity and the exposition of membrane protein receptors in Alzheimer disease (AD) patients--preliminary Study. Alzheimer Dis Assoc Disord 2002; 16 (01) 52-54
    CrossrefPubMedGoogle Scholar
  • 52 Stellos K, Panagiota V, Kögel A, Leyhe T, Gawaz M, Laske C. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab 2010; 30: 1817-1820
    PubMedGoogle Scholar
  • 53 Boyano I, Bravo N, Miranda J, Gil-Gregorio P, Olazarán J. Brain microbleeds: epidemiology and clinical implications [in English, Spanish]. Neurologia 2018; 33 (08) 515-525
    CrossrefPubMedGoogle Scholar
  • 54 Mari D, Coppola R, Provenzano R. Hemostasis factors and aging. Exp Gerontol 2008; 43 (02) 66-73
    CrossrefPubMedGoogle Scholar
  • 55 Vaccarino L, Forte GI, Palmeri M. , et al. Role of prothrombotic polymorphisms in successful or unsuccessful aging. Biogerontology 2011; 12 (05) 445-450
    CrossrefPubMedGoogle Scholar
  • 56 Moretti R, Caruso P, Dal Ben M, Conti C, Gazzin S, Tiribelli C. Vitamin D, homocysteine, and folate in subcortical vascular dementia and Alzheimer dementia. Front Aging Neurosci 2017; 9: 169
    CrossrefPubMedGoogle Scholar
  • 57 van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005; 36 (12) 2637-2641
    CrossrefPubMedGoogle Scholar
  • 58 Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 2012; 32 (03) 599-608
    CrossrefPubMedGoogle Scholar
  • 59 Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging 2015; 36 (02) 608-617
    CrossrefPubMedGoogle Scholar
  • 60 Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol 2016; 15 (09) 934-943
    CrossrefPubMedGoogle Scholar
  • 61 Ferreira CN, Sousa MO, Dusse LMSA, Carvalho MG. A cell-based model of coagulation and its implications. Rev Bras Hematol Hemoter 2010; 32: 416-421
    PubMedGoogle Scholar
  • 62 Veitinger M, Varga B, Guterres SB, Zellner M. Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?. Acta Neuropathol Commun 2014; 2: 65
    CrossrefPubMedGoogle Scholar
  • 63 Talib LL, Joaquim HP, Forlenza OV. Platelet biomarkers in Alzheimer's disease. World J Psychiatry 2012; 2 (06) 95-101
    PubMedGoogle Scholar
  • 64 Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer's disease correlates with coated-platelet levels--a longitudinal study. Transl Res 2008; 152 (03) 99-102
    CrossrefPubMedGoogle Scholar
  • 65 Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364 (18) 1746-1760
    CrossrefPubMedGoogle Scholar